Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

ERT Support for New Drug Development Exceeds 10,000 Studies

publication date: Nov 14, 2017
 | 
author/source: ERT

Extensive experience enables biopharmaceutical researchers to better navigate clinical trial complexities and minimize risks

ERTERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, has announced it has reached a significant milestone in its nearly 50 year history: Global biopharmaceutical companies and contract research organizations (CROs) have relied on the company to accelerate their clinical development timelines in more than 10,000 studies worldwide.

“It’s truly an honor to support our customers’ important clinical development programs as they develop new medical treatments,” said James Corrigan, President and CEO, ERT. “We’re privileged to have earned their trust and to have played a role in their successes at bringing life-saving and life-enhancing drugs to the patients who need them.”

To date, ERT’s solutions have been used in clinical development programs that supported over 550 new drug approvals, including more than half of FDA approvals over the past four years. More than three million patients spanning 235,000 investigative sites around the world have used ERT’s trial oversight, patient engagement, site optimization and safety/efficacy solutions across a wide range of therapeutic areas, including oncology, CNS and immunology, among others.

“There has been significant growth in the global adoption of technology-driven solutions over the past five years, and this trend will continue as more and more biopharmaceutical companies recognize the benefits that proven technologies offer over traditional, paper-based methods,” stated Corrigan. “We look forward to continue helping customers navigate through clinical trial complexities, anticipate potential challenges, and quickly adapt to address them.  All of this has a meaningful impact on drug development and the amazing work they do every day.”   


more about ERT


more news from ERT


 

 

 


If you have not logged into the website then please enter your details below.



 

News Channels

 

 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 

 

 

 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events